Related Experiment Video

Updated: Jun 4, 2025

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
08:10

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

7.8K

Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report

Daniel Cool1, James Coventon1,2, Abhishek Sharma3

  • 1Ophthalmology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Case Reports in Ophthalmological Medicine
|December 18, 2024
PubMed
Summary

Semaglutide treatment led to the regression of proliferative diabetic retinopathy (PDR) and improved diabetic macular oedema (DMO) in a patient with type 2 diabetes. This suggests semaglutide may have an independent role in managing PDR.

Keywords:
GLP-1 receptor agonistsdiabetic macular odema (DMO)diabetic retinopathyproliferative diabetic retinopathy (PDR)semaglutide

More Related Videos

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature06:09

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

212
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.7K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167